再生医学新突破!全球可自我繁殖的活体机器人问世,AI 立了大功

2021-12-02 生物探索 生物探索

关注!

在我们眼中,机器人从来都是由金属材料制成,这些材料可以让机器人既强壮又灵活。而现在,一种新型异种机器人已经诞生,来自美国佛蒙特大学、塔夫茨大学和哈佛大学的研究团队研发出了有史以来第一款可自我繁衍的活体机器人,它完全打破了人们对于机器人的固有印象,并且有望在未来为外伤、先天缺陷、癌症、衰老等提供更直接、更个性化的药物治疗。这项研究成果以“Kinematic self-replication in reconfigurable organisms”为题发表于《美国国家科学院院刊》上。

图片文献DOI https://doi.org/10.1073/pnas.2112672118

这款活体机器人名为Xenobot,在去年就有了初代设计,科学家们利用从青蛙胚胎中提取的活细胞,将它们组装成全新的生命形式。根据当时的介绍,这款机器人可以被看作是一种活的、可编程有机体,主要是为了帮助解决化合物或放射性污染、海洋微塑料污染等生态环境问题。而今年的最新研究,则有了新的突破,Xenobot可自我复制,同时移速更快,寿命更长,能更好地适应各种环境。

在此项研究中,科学家们从非洲爪蟾胚胎中提取活干细胞,让它们孵化成心脏细胞和表皮细胞,单独培养后再将两种细胞拼凑在一起,形成由大约3000个细胞组成的母体异形机器人,此时的机器人还只是一个球体,能够进行螺旋移动,而将干细胞放在机器人四周时,它能够聚集更多干细胞成为子代,这样的繁衍能够持续1-2代。不过,虽然母体异型机器人能够进行繁衍,但是不能进行系统性繁殖,为了解决这一问题,科学家们采用了智能AI 

研究人员在佛蒙特州高级计算核心的Deep Green超级计算机集群上运行的人工智能程序,对活体机器人的形态进行算法构建,进化算法能够在模拟中测试数十亿种形态,如三角形、正方形、金字塔形状、海星形状等,旨在找到可以让细胞运动学自我复制更有效的形状。

图片

图注:Deep Green对活体机器人进行的多种模型构建

经过模拟测试后,一种类似吃豆人形态的活体机器人诞生了,当将它们放入满是干细胞的培养皿中,这些机器人可以随意游动,将数百个干细胞聚集在一起,然后在它们C字型的里组装新的子代异形机器人。在经过几天的培养后,这些新的子代异形机器人已经可以繁衍更多的小机器人,而这些吃豆人活体机器人最多能繁衍4代,同时,其产生的后代直径也比球形Xenobot的后代大50%左右。

图片

图注:红色为Xenobot活体机器人,绿色为干细胞

图片

图注:Xenobot的运动轨迹,与初代设计的形态对比,以及与初代设计的自我复制能力对比

针对这一研究,团队成员Michael Levin教授提到,这项研究让人们看到了再生医学进步的希望。如果我们知道如何告诉细胞群做我们想让它们做的事情,这将为外伤、先天缺陷、癌症和衰老等疾病的治疗提供更佳解决方案,目前的问题在于,我们要学会如何预测和控制将要构建的细胞群,而Xenobots 将成为一个新的研究教学平台。

科学家们希望,这一新型活体机器人能够成为智能药物输送或内外科手术的新型载体。在生物医学环境中,这种生物机器人如果由患者自己的细胞制成,或许能够从动脉壁去除斑块,识别癌症,甚至安顿下来以区分或控制疾病位置。这种结构的一个有益安全特征是,在没有特定代谢工程的情况下,它们的寿命自然有限,可以自行被代谢掉。

面对这一研究成果,有些人会觉得令人振奋,也有一部分人对自我复制生物技术的概念感到担忧,甚至恐惧,害怕这些活体机器人会在不受控制的情况下引发灾难。对于这一质疑,团队成员Joshua Bongard教授给予了解释:我们正在努力了解细胞自我复制这个特性,对于整个社会来说,研究和了解它是如何运作的显得尤为重要。这些毫米大小的活体机器人受控于实验室条件,很容易被销毁,并且会由联邦、州立机构的伦理专家进行监督审查,我们也有道德义务去了解和研究控制它、引导它、消灭它的条件。

虽然会有担忧与风险,我们也不能完全忽视这一研究包含的两项重要成果,首先,智能AI在此次研究中功不可没,人工智能可以通过多种随机组合来探究最适合的模型,以帮助人类在短时间内找到最佳问题解决方案;其次,此次的研究打破了人们对于生命繁衍的固有认知,细胞通过分裂进行复制是公认的繁衍方式,但是此次干细胞的自我复制是科学家们首次观察到的一种新的繁衍方式,正如科学家们在《美国国家科学院院刊》研究中所写的那样:生命在表面之下隐藏着令人惊讶的行为,等待被发现。

参考资料:

[1]https://techxplore.com/news/2021-11-xenobots-team-robots.html

[2]https://techxplore.com/news/2020-01-team-robots.html

[3]https://www.pnas.org/content/118/49/e2112672118

[4]https://www.jiemian.com/article/6865804.html

[5]https://mp.weixin.qq.com/s/ofgiKEyVSZ965hswKT1rtA

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1322171, encodeId=6f4a13221e11d, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583346, encodeId=f7ad158334697, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076446, encodeId=e71b10e6446c9, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725065, encodeId=8b661e2506580, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Sep 28 17:42:12 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076341, encodeId=53d410e634179, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Dec 02 21:56:02 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-04 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1322171, encodeId=6f4a13221e11d, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583346, encodeId=f7ad158334697, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076446, encodeId=e71b10e6446c9, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725065, encodeId=8b661e2506580, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Sep 28 17:42:12 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076341, encodeId=53d410e634179, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Dec 02 21:56:02 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1322171, encodeId=6f4a13221e11d, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583346, encodeId=f7ad158334697, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076446, encodeId=e71b10e6446c9, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725065, encodeId=8b661e2506580, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Sep 28 17:42:12 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076341, encodeId=53d410e634179, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Dec 02 21:56:02 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-03 查查佳佳

    春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1322171, encodeId=6f4a13221e11d, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583346, encodeId=f7ad158334697, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076446, encodeId=e71b10e6446c9, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725065, encodeId=8b661e2506580, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Sep 28 17:42:12 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076341, encodeId=53d410e634179, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Dec 02 21:56:02 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-09-28 zxxiang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1322171, encodeId=6f4a13221e11d, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583346, encodeId=f7ad158334697, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Sat Dec 04 12:42:12 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076446, encodeId=e71b10e6446c9, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:40 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725065, encodeId=8b661e2506580, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Wed Sep 28 17:42:12 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076341, encodeId=53d410e634179, content=认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Dec 02 21:56:02 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 医鸣惊人

    认真学习了。

    0

相关资讯

JNER:使用一种上肢康复游戏机器人系统用于中风患者康复

中风是全世界死亡、身体残疾的主要原因之一。在过去几年中,中风患者的患病率有所增加,从而对康复有了更高的需求。上肢瘫痪是中风后常见的损伤,只有10-20%的患者完全康复:对于这些患者,手臂康复的主要目的

JNER:机器人强化中风治疗的康复策略—一项初步研究

中风康复的绝大多数临床试验都集中于慢性中风患者。虽然中风后慢性期的治疗已被证明可减少运动损伤,但亚急性期似乎出现了改善运动能力的重大机会。研究表明,亚急性中风的强化干预可以提高运动能力的恢复。目前的研

JNER:虚拟现实、机器人和电刺激联合干预上肢卒中康复的可行性和初步疗效

结果表明虚拟现实、机器人和电刺激有助于改善中风所致中重度损害患者的UE功能。

中国首例机器人全膝人工关节置换手术在京完成

记者从中国科学技术协会获悉,中国首例机器人全膝人工关节置换(TKA)手术近日在北京完成。此次使用的HURWA关节手术机器人是中国自行研发的具有完全自主知识产权的现代尖端科技医用设备。 据介绍,该手术由北京协和医院关节外科林进、王炜团队实施。在麻醉科、手术室、放射科等相关科室和职能处室的合作下,“中国造”关节机器人完成了此次“首秀”。全膝人工关节置换手术技术要求高、操作难度大,而TKA手术

JNER:机器人训练有助于急性脑卒中患者运动功能恢复的生理机制

中风后遗留的半身不遂,需要进行康复训练,才能使部分机体功能得到恢复。大约60%的患者在中风后6个月后依然无法恢复。到目前为止,已经有多种康复疗法,如运动疗法、镜像疗法、虚拟现实、神经-肌肉电刺激。此外